Bristol Myers Squibb Company $BMY Stock Sold by Conning Inc.

Conning Inc. reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 12.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 592,876 shares of the biopharmaceutical company’s stock after selling 86,136 shares during the quarter. Conning Inc.’s holdings in Bristol Myers Squibb were worth $36,995,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Sigma Investment Counselors Inc. bought a new position in shares of Bristol Myers Squibb during the third quarter worth about $213,000. William Mack & Associates Inc. acquired a new stake in Bristol Myers Squibb in the 3rd quarter valued at approximately $35,000. Victory Financial Group LLC bought a new stake in Bristol Myers Squibb in the 3rd quarter valued at approximately $228,000. Great Lakes Retirement Inc. bought a new stake in Bristol Myers Squibb in the 3rd quarter valued at approximately $2,173,000. Finally, Generali Asset Management SPA SGR lifted its stake in Bristol Myers Squibb by 4.2% in the 3rd quarter. Generali Asset Management SPA SGR now owns 265,264 shares of the biopharmaceutical company’s stock valued at $16,552,000 after acquiring an additional 10,647 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on BMY. Zacks Research downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 22nd. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 13th. Piper Sandler cut their price objective on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a research report on Monday. Guggenheim reissued a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Finally, Morgan Stanley restated an “underweight” rating and set a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a report on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $65.50.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $60.51 on Thursday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The business has a 50-day moving average of $62.98 and a 200-day moving average of $59.88. The stock has a market capitalization of $123.59 billion, a price-to-earnings ratio of 13.33, a PEG ratio of 0.31 and a beta of 0.19. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb’s revenue was up 5.7% on a year-over-year basis. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.51 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: A Bristol Myers Squibb cancer drug reportedly doubled progression-free survival in a study and also showed encouraging results in other solid tumors. The data could strengthen the company’s growth portfolio and help offset concerns about future product declines. Bristol Myers Squibb Cancer Drug Trial Article
• Positive Sentiment: One valuation analysis argues that BMY still trades below its estimated fair value and highlights the company’s cash-generation potential. That view may attract value-oriented investors following the stock’s substantial one-year advance. Bristol Myers Squibb Fair Value Analysis
• Neutral Sentiment: Bristol Myers Squibb is scheduled to report third-quarter results before the market opens Thursday. Pre-earnings coverage is focused on revenue, earnings, full-year guidance and performance from key growth products, making the report the next major catalyst for BMY. Bristol Myers Squibb Q3 2026 Earnings Preview
• Neutral Sentiment: Analyst opinions remain divided. A consolidated fair-value estimate fell from $66.71 to $65.25, while individual targets range from the $50s to the $80s, reflecting differing expectations for pipeline data, potential corporate actions and future cash flows. Bristol Myers Squibb Fair Value and Analyst Views
• Negative Sentiment: Piper Sandler cut its price target for BMY, adding pressure to the shares ahead of earnings. The target reduction suggests more cautious expectations for near-term operating performance or the company’s pipeline. Piper Sandler Price Target Cut
• Negative Sentiment: Zacks Research made small cuts to its fiscal 2027 and 2028 EPS estimates and maintains a “Hold” rating. The lower forecasts reinforce concerns that earnings may decline beyond the current year, when analysts expect approximately $6.51 per share. Bristol Myers Squibb Analyst Estimates

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.